NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · LARGE CAP
Sndl Inc. SNDL
8 fiscal years on record · CAD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
CAD 946.4M
▲ 2.8% vs FY2024
EPS · FY25
CAD -0.06
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-1.4%
Net margin · FY25
-1.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CAD 946.4M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 2 cents on every revenue dollar this year.
Per share
CAD -0.06
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-1.4%
Return on equity, FY2025
ROE
Operating margin-0.7%
Net margin-1.7%
Return on assets-1.2%
Each CAD of equity lost 1 cents this year.
Returned to shareholders
CAD 15.3M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksCAD 15.3M
Share of profit-97.3%
Consecutive raises—
CAD 15.3M in buybacks went back to shareholders in a year without profit.
Growth
+73.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.9%
+73.1%
Returned to shareholders
+13.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CAD 1.3B
total assets, end of FY2025
Total assetsCAD 1.3B
EquityCAD 1.1B
CashCAD 252.2M
Current ratio4.88×
Equity funds 82% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · CAD
Metric
2025
2024
2023
2022
2021
2020
2019
2017
Revenue CAD B
0.9
0.9
0.9
0.7
0.1
0.1
0.1
·
Operating income CAD B
−0.0
−0.1
−0.2
−0.3
−0.1
−0.2
−0.1
−0.0
EBITDA CAD B
0.0
−0.0
−0.1
−0.3
−0.1
−0.2
−0.1
−0.0
Income tax CAD B
·
·
·
·
·
·
·
·
Net income CAD B
−0.0
−0.1
−0.2
−0.3
−0.2
−0.2
−0.3
−0.0
EPS, diluted CAD
−0.06
−0.36
−0.67
−1.46
·
·
·
·
Dividend / sh CAD
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−1.4
−8.1
−13.7
−25.4
−28.4
−95.6
−260.3
·
Shares out B
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed